A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
PHASE2CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
October 31, 2015
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Conditions
Hepatitis C Viral InfectionChronic Hepatitis CHepatitis C (HCV)Hepatitis C Genotype 4
Interventions
DRUG
Faldaprevir
DRUG
TD-6450
DRUG
Ribavirin
Trial Locations (1)
92118
Southern California Research Center, Coronado
All Listed Sponsors
lead
Trek Therapeutics, PBC
INDUSTRY
NCT02593162 - A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection | Biotech Hunter | Biotech Hunter